Physician profile
Amanda Lilly
NPI 1003290206
$1,362.09
in general payments reported to CMS, 2019-2025
20 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.88 · 2022: $19.61 · 2023: $478 · 2024: $310 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.33 | 2021-2025 | |
| Gilead Sciences, INC. | $190.70 | 2023-2025 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $111.21 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Indivior INC. | $107.58 | 2023-2025 | Perseris, Sublocade |
| Lundbeck LLC | $84.08 | 2024-2025 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.89 | 2024-2025 | Caplyta |
| Dexcom, INC. | $65.08 | 2021-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $57.90 | 2023-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $50.42 | 2021-2024 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $47.16 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $46.18 | 2023-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $43.94 | 2024 | Spravato |
| Xeris Pharmaceuticals, INC. | $37.40 | 2024-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.21 | 2025 | Xifaxan |
| Alkermes, INC. | $34.54 | 2022-2023 | Aristada, Lybalvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $21.41 | 2025 | Fanapt |
| Viiv Healthcare Company | $19.52 | 2024 | Apretude |
| Exact Sciences Corporation | $19.16 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $18.42 | 2025 | Ozempic |
| Biohaven Pharmaceuticals, INC. | $15.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.